Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432802 | 1.00 | TDP1 (0.47) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL15221112 | 0.81 | TDP1 (0.42) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL2258709 | 0.81 | TSHR (0.44) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL30072914 | 0.81 | TSHR (0.44) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL1749639 | 0.81 | TDP1 (0.44) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL31364996 | 0.78 | TDP1 (0.44) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL30890730 | 0.78 | CTSB (0.53) | TDP1ATMALDH1A1TSHRCYP3A4 | |
| SCHEMBL9982714 | 0.78 | CTSB (0.53) | TDP1ATMALDH1A1TSHRCYP3A4 | |
| SCHEMBL6990761 | 0.78 | MAPT (0.49) | TDP1ATMALDH1A1HIF1ATSHR | |
| SCHEMBL6837266 | 0.78 | CTSB (0.42) | TDP1ATMALDH1A1HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
| WO-2001096338-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-20 | — | — | WO | disclosed |
| US-5866589-A | Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5133798-A | Certain herbicidal 1,2,4-triazolo[4,5-b]pyridines | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| EP-0453065-A1 | Triazolopyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
| US-4225713-A | HYPOTENSIVE AGENTS | FREED MEIER E | 1980-09-30 | — | — | US | disclosed |
| US-4144341-A | ANTIPYRETICS, ANALGESICS AND ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4138564-A | HYPOTENSIVE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TDP1 1466/4885ATM 1026/4885ALDH1A1 959/4885 |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | LRRK2, PINK1, PSMC1 | TDP1 2547/4885ATM 326/4885ALDH1A1 3606/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | TDP1 3310/4885ATM 246/4885ALDH1A1 3225/4885 |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | TDP1 292/4885ATM 3914/4885ALDH1A1 1770/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | TDP1 1186/4885ATM 1082/4885ALDH1A1 1225/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | TDP1 1465/4885ATM 2235/4885ALDH1A1 1790/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | TDP1 2693/4885ATM 2224/4885ALDH1A1 721/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | TDP1 2817/4885ATM 2152/4885ALDH1A1 765/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TDP1 1466/4885ATM 1026/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.